P1220 MODELING PREDICTS CLINICALLY MEANINGFUL SVR RATES IN GENOTYPE 1 TREATMENT-EXPERIENCED PATIENTS BASED ON RESULTS IN GENOTYPE 1 TREATMENT-NAIVE PATIENTS TREATED WITH SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS

Methods: Three hundred HCV patients and 860 family members were studied. All family members were screened for HCV antibodies by ELISA. Positive cases were examined using Real-Time PCR to confirm the presence of HCV-RNA. Seventy five patients of 300 were treated using SOC treatment. Molecular study of IL-28B gene was done to all patients and their families using PCR and restriction enzyme analysis. Results: IL-28B gene (rs12979860) polymorphism in patients was 27.43%, 55.43% and 17.14% for C/C, C/T and T/T genotypes respectively, in non infected family members was 37.38%, 44.05% and 18.57% for C/C, C/T and T/T respectively. There was significant increase as regard CC genotype in non-infected family members than patients. Of the treated 75 patients, 36 achieved SVR (48%). Better response to treatment was found in CC genotype (75%) than CT (48%) and TT (28.5%). Conclusions: CC genotype for IL-28B gene has better response to treatment and may have a protective role against HCV infection as it detected significantly in non infected family members of HCV patients. Acknowledgement: Project was funded by Science, Technology Development Fund (STDF), Egypt, Grant No. 1687.